definiens: means one of the Original Program Licences or Additional Program Licences ; and means any combination of two or more of the foregoing, as the context requires ; means ( i ) those materials identified in Part E of Schedule 2 ; ( ii ) those materials generated or developed by AN or AN Laboratory as of the Effective Date t hrough use of, or forming part of, the Program IP, or otherwise developed or generated by AN or AN Laboratory under or pursuant to any Program ; and ( iii ) with respect to the Second Serotype Option Program, those materials generated or developed by AN or AN Laboratory prior to, on or after the Effective Date but up until the date of exercise of the Second Serotype Option, or forming part of, the Second Serotype Program IP, or otherwise developed or generated by AN or AN Laboratory under or pursuant to the Se cond Serotype Program IP ; and ( iv ) with respect to the Additional Programs, those materials identified in part F of Schedule 2 under the title Additional Program Materials ; has the meaning set out in Clause 2.4.5 ; means ( i ) those patent applications listed in Part A of Schedule 2 under the title ‘ Promoter Patents ’ and all Patent Rights derived therefrom ; and ( ii ) any Future Patents filed in respect of HLP2, and/or any of the Program Know -How identified in ( ii ) of the definition of Promoter Program IP ; means, excluding any Additional Royalty Product, any AAV gene therapy product which is covered by, incorporates in it or uses in its manufacture any of the Promoter Program IP licensed to Liverco hereunder ; means the program of research as conducted prior to the Effective Date and resulting in patent applications listed in Part A of Schedule 2 under the title ‘ Promoter Patents ’ ; means means the Promoter P atent Rights, and ( ii ) Program Know -How existing at the Effective Date applicable to HLP2 and Exploitation thereof ; means any method or material that has been provided to the AN Laboratory by [ * * ] ; has the meaning se t out in Clause 15.9 ; or a period of three calendar months each ending on 31 March, 30 June, 30 September or 31 December ; has the meaning set out in Clause 17.1 ; has the meaning set out in paragraph 1 of Part B Schedule 8 ; 18 Certain confidential information contained in this document, marked by [ * * ], has been omitted because the information ( i ) is not material and ( ii ) would likely cause competitive harm to the Company if publicly disclosed